RxDoctor Payments Data

Vasilios Lazos, DO

Ophthalmology · Manchester, NHNPI 1285613521

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Johnson & Johnson Surgical Vision, Inc. accounts for 64.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $2,371 and has fallen 97.2% since, to $67 in 2025.

$3,573in general payments, 2019–2025

Across 59 payments — averaging $60.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$390
  • Genentech USA, Inc.$111
  • Ivantis, Inc$92
  • Boston Scientific$92
  • Oyster Point Pharma, Inc.$67
  • plus $503 from 14 others

What the payments were for

  • Consulting fees$2,13260%
  • Food & beverage$1,43040%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,573 in reported general payments places this provider in the 70th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$361,149
Medicare patients
965
Services billed
2,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine68$85,058
Cyclosporine60$35,633
LumiganBimatoprost55$30,768
XiidraLifitegrast28$27,985
Alphagan PBrimonidine Tartrate18$11,961
Prednisolone Acetate252$8,701
Latanoprost440$4,601
Travoprost20$4,254
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat130$2,712
Brinzolamide13$2,647
Timolol Maleate150$2,508
Ketorolac Tromethamine138$2,385
Brimonidine Tartrate50$2,047
Difluprednate11$1,730
Fluorometholone21$1,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$30$127,787141 claims
Bausch & Lomb Americas Inc.Xiidra$65$27,98528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →